Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: Phase II randomized controlled trial in Singapore

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 9, 2012, Pages 1259-1271

  Leo, Yee Sin ^a   Wilder Smith, Annelies ^b,c   Archuleta, Sophia ^b,c   Shek, Lynette P ^d   Chong, Chia Yin ^e   Leong, Hoe Nam ^f   Low, Chian Yong ^f   Oh, May Lin Helen ^g   Bouckenooghe, Alain ^h   Wartel, T Anh ⁱ   Crevat, Denis ^j  

^a TAN TOCK SENG HOSPITAL   (Singapore)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e KK WOMEN'S AND CHILDREN'S HOSPITAL   (Singapore)

^f SINGAPORE GENERAL HOSPITAL   (Singapore)

^g CHANGI GENERAL HOSPITAL   (Singapore)

^h Clinical R and D   (Singapore)

ⁱ Clinical R and D   (Thailand)

^j SANOFI PASTEUR   (France)

more..

Author keywords

CYD vaccine; Dengue; Immunogenicity; Phase II trial; Recombinant live vaccine; Safety; Singapore; Tetravalent dengue vaccine

Indexed keywords

DENGUE VACCINE; HEPATITIS A VACCINE; INFLUENZA VACCINE; LIVE VACCINE; PLACEBO; RECOMBINANT TETRAVALENT DENGUE VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; ASTHENIA; CELLULAR IMMUNITY; CHILD; CONTROLLED STUDY; DENGUE; DENGUE VIRUS; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DENGUE VIRUS 4; DOSE RESPONSE; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; GEOMETRIC MEAN NEUTRALIZING ANTIBODY TITER; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOLOGICAL PARAMETERS; INJECTION SITE ERYTHEMA; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; MALAISE; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; PHASE 2 CLINICAL TRIAL; POPULATION RESEARCH; PRESCHOOL CHILD; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SINGAPORE; SINGLE BLIND PROCEDURE; VACCINATION;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DENGUE; DENGUE VACCINES; FEMALE; HUMANS; MALE; MIDDLE AGED; SINGAPORE; YOUNG ADULT;

EID: 84867009128     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.21224     Document Type: Article

References (42)

1. Schweitzer BK, Chapman NM, Iwen PC. Overview of the Flaviviridae with an emphasis on the Japanese Encephalitis group viruses. Lab Med 2009; 40:493-9; http://labmed.ascpjournals.org/content/40/8/493.full.pdf; http://dx.doi.org/10. 1309/LM5YWS85NJPCWESW.
2. Mackenzie JS, Gubler DJ, Petersen LR. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat Med 2004; 10(Suppl):S98-109; PMID:15577938; http://dx.doi.org/10.1038/nm1144.
3. World Health Organization. Dengue hemorrhagic fever: diagnosis, treatment, prevention and control, 2nd Edn. Geneva: World Health Organization. 2009. Available at: http://whqlibdoc.who.int/publications/2009/9789241547871- eng.pdf.
4. Green S, Rothman A. Immunopathological mechanisms in dengue and dengue hemorrhagic fever. Curr Opin Infect Dis 2006; 19:429-36; PMID:16940865; http://dx.doi.org/10.1097/01.qco.0000244047.31135.fa.
5. Kurane I. Dengue hemorrhagic fever with special emphasis on immunopathogenesis. Comp Immunol Microbiol Infect Dis 2007; 30:329-40; PMID:17645944; http://dx.doi.org/10.1016/j.cimid.2007.05.010.
6. World Health Organization. Dengue and dengue haemorrhagic fever, Factsheet number 117 (Revised March 2009). 2009a. Available at: http://www.who.int/mediacentre/factsheets/fs117/en/index.html.
7. World Health Organization. Global Alert and Response (GAR): Impact of Dengue. 2012. Available at: http://www.who.int/csr/disease/dengue/impact/en/.
8. Halstead SB. Dengue. Lancet 2007; 370:1644-52; PMID:17993365; http://dx.doi.org/10.1016/S0140-6736(07)61687-0.
9. Guzman MG, Halstead SB, Artsob H, Buchy P, Farrar J, Gubler DJ, et al. Dengue: a continuing global threat. Nat Rev Microbiol 2010; 8(Suppl):S7-16; PMID:21079655; http://dx.doi.org/10.1038/nrmicro2460.
10. SEARO. Situation update of dengue in the SEA Region, 2010. Available at: http://www.searo.who.int/LinkFiles/Dengue-Dengue-update-SEA-2010.pdf.
11. Halstead SB. Dengue in the Americas and Southeast Asia: do they differ? Rev Panam Salud Publica 2006; 20:407-15; PMID:17341332; http://dx.doi.org/10. 1590/S1020-49892006001100007.
12. Wilder-Smith A, Gubler DJ. Geographic expansion of dengue: the impact of international travel. Med Clin North Am 2008; 92:1377-90, x; PMID:19061757; http://dx.doi.org/10.1016/j.mcna.2008.07.002.
13. Whitehead SS, Blaney JE, Durbin AP, Murphy BR. Prospects for a dengue virus vaccine. Nat Rev Microbiol 2007; 5:518-28; PMID:17558424; http://dx.doi.org/10.1038/nrmicro1690.
14. Guy B, Saville M, Lang J. Development of Sanofi Pasteur tetravalent dengue vaccine. Hum Vaccin 2010; 6:696-705; PMID:20861669; http://dx.doi.org/10. 4161/hv.6.9.12739.
15. Guy B, Barrere B, Malinowski C, Saville M, Teyssou R, Lang J. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 2011; 29:7229-41; PMID:21745521; http://dx.doi.org/10.1016/j.vaccine.2011.06.094.
16. Guirakhoo F, Weltzin R, Chambers TJ, Zhang ZX, Soike K, Ratterree M, et al. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol 2000; 74:5477-85; http://jvi.asm.org/ content/74/12/5477. full.pdf; PMID:10823852; http://dx.doi.org/10.1128/JVI.74. 12.5477-5485.2000.
17. Guirakhoo F, Arroyo J, Pugachev KV, Miller C, Zhang ZX, Weltzin R, et al. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J Virol 2001; 75:7290-304; http://jvi.asm.org/content/75/16/7290.full.pdf; PMID:11462001; http://dx.doi.org/10.1128/JVI.75.16.7290-7304.2001.
18. Guy B, Guirakhoo F, Barban V, Higgs S, Monath TP, Lang J. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 2010; 28:632-49; PMID:19808029; http://dx.doi.org/10.1016/j.vaccine.2009.09.098.
19. Qiao M, Shaw D, Forrat R, Wartel-Tram A, Lang J. Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans. Am J Trop Med Hyg 2011; 85:724-31; http://www.ajtmh.org/content/85/4/724.full.pdf; PMID:21976579; http://dx.doi.org/10.4269/ajtmh.2011.10-0436.
20. Guirakhoo F, Kitchener S, Morrison D, Forrat R, McCarthy K, Nichols R, et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vacc 2006; 2:60-7. Available at: http://www. landesbioscience.com/journals/vaccines/guirak-hooHV2-2.pdf.
21. Morrison D, Legg TJ, Billings CW, Forrat R, Yoksan S, Lang J. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavi-virus-naive adults. J Infect Dis 2010; 201:370-7; http://jid.oxfordjournals.org/content/201/3/370.full.pdf; PMID:20059357; http://dx.doi.org/10.1086/649916.
22. Crevat D, Reynolds D, Langevin E, Capeding MR. Safety and immunogenicity of a tetravalent dengue vaccine in flavivirus-naïve and immune paediatric populations with two vaccination regimens. [Abstract 395]. Am J Trop Med Hyg 2009; 81(Suppl 1):113.
23. Forrat R, Poo JL, Galán Herrera JF. Immune response to tetravalent dengue vaccination in Mexican subjects: the effects of yellow fever vaccination. [Abstract 387]. Am J Trop Med Hyg 2008; 79(Suppl 6):114.
24. Wilder-Smith A, Foo W, Earnest A, Sremulanathan S, Paton NI. Seroepidemiology of dengue in the adult population of Singapore. Trop Med Int Health 2004; 9:305-8; http://onlinelibrary.wiley.com/doi/10.1046/j.1365-3156. 2003.01177.x/pdf; PMID:15040570; http://dx.doi.org/10.1046/j.1365-3156.2003. 01177.x.
25. Burattini MN, Chen M, Chow A, Coutinho FA, Goh KT, Lopez LF, et al. Modelling the control strategies against dengue in Singapore Epidemiol Infect 2008; 136:309-19. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/ PMC2870819/pdf/S0950268807008667a.pdf.
26. Ooi EE, Goh KT, Gubler DJ. Dengue prevention and 35 years of vector control in Singapore. Emerg Infect Dis 2006; 12:887-93; PMID:16707042; http://dx.doi.org/10.3201/10.3201/eid1206.051210.
27. Goh KT. Dengue--a re-emerging infectious disease in Singapore. Ann Acad Med Singapore 1997; 26:664-70; PMID:9494676.
28. Lee KS, Lai YL, Lo S, Barkham T, Aw P, Ooi PL, et al. Dengue virus surveillance for early warning, Singapore. Emerg Infect Dis 2010; 16:847-9; http://wwwnc.cdc.gov/eid/article/16/5/09-1006-article.htm; PMID:20409381.
29. World Health Organization Western Pacific Region. Cases of dengue, including imported cases, and dengue-attributed deaths in the Western Pacific Region for 2010. Available at: http://www2.wpro.who.int/NR/rdonlyres/F05F1AFF- 8D7B-4251-A64F-85809938DEE1/0/Table1201122005-RA-Denguesurv-WPR.jpg.
30. Singapore Ministry of Health. Communicable Diseases Surveillance in Singapore 2010: Annual Report. Chapter II. Vector-Borne Diseases. Surveillance of dengue virus serotypes, 1992-2010; p33. Available at: http://www.moh.gov.sg/ content/dam/moh-web/Publications/Reports/2011/ Communicable%20Diseases%20Surveillance%20in%20Singapore%202010/ Vector-borne%202010.pdf.
31. Singapore Ministry of Health. Review of Singapore's dengue prevention and control programme. Epidemiol News Bull (October-December) 2006; 32. Available at: http://www.moh.gov.sg/content/dam/moh-web/Statistics/Epidemiological-News- Bulletin/2006/ENB04Q-06.pdf.
32. Beatty M, Letson W, Edgil D, Margolis H. Estimating the total world population at risk for locally acquired dengue infection. Abstract presented at the 56th Annual Meeting of the American Society of Tropical Medicine and Hygiene. ASTMH Abstract Book 2007; Abstract 768: 221. Available at: http://www.astmh.org/AM/Template.cfm?Section=Meeting-Archives&Template=/CM/ ContentDisplay.cfm&ContentID=1514
33. Poo J, Galan F, Forrat R, Zambrano B, Lang J, Dayan GH. Live-attenuated tetravalent dengue vaccine in dengue-naïve children, adolescents, and adults in Mexico City: randomized controlled phase 1 trial of safety and immunogenicity. Pediatr Infect Dis J 2010; 30:e9-17; PMID:21042231; http://dx.doi.org/10.1097/INF.0b013e3181fe05af.
34. Capeding RZ, Luna IA, Bomasang E, Lupisan S, Lang J, Forrat R, et al. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines. Vaccine 2011; 29:3863-72; PMID:21477675; http://dx.doi.org/10.1016/ j.vaccine.2011.03.057.
35. Klein SL, Jedlicka A, Pekosz A. The Xs and Y of immune responses to viral vaccines. [Erratum in: Lancet Infect Dis. 2010;10:740]. Lancet Infect Dis 2010; 10:338-49; PMID:20417416; http://dx.doi.org/10.1016/S1473-3099(10)70049-9.
36. Edelman R, Hombach J. "Guidelines for the clinical evaluation of dengue vaccines in endemic areas": summary of a World Health Organization Technical Consultation. Vaccine 2008; 26:4113-9; PMID:18597906; http://dx.doi.org/10.1016/j.vaccine.2008.05.058.
37. World Health Organization. Guidelines for the clinical evaluation of dengue vaccine in endemic areas, WHO/IVB/08.12. 2008. Available at: http://whqlibdoc.who.int/hq/2008/WHO-IVB-08.12-eng.pdf.
38. World Health Organization. Guidelines on the Quality, Safety and Efficacy of Dengue Tetravalent Vaccines (Live, Attenuated). WHO/BS/11.2159. Geneva: WHO; 2011. Accessed at http://www.who.int/biologicals/BS2159-Dengue-WITH-LINE- NUMBERS-TRS-v47-18Jul2011-sub2.pdf.
39. Mantel N, Aguirre M, Gulia S, Girerd-Chambaz Y, Colombani S, Moste C, et al. Standardized quantitative RT-PCR assays for quantitation of yellow fever and chimeric yellow fever-dengue vaccines. J Virol Methods 2008; 151:40-6; PMID:18501437; http://dx.doi.org/10.1016/j.jviromet.2008.03.026.
40. Huhtamo E, Hasu E, Uzcátegui NY, Erra E, Nikkari S, Kantele A, et al. Early diagnosis of dengue in travelers: comparison of a novel real-time RT-PCR, NS1 antigen detection and serology. J Clin Virol 2010; 47:49-53; PMID:19963435; http://dx.doi.org/10.1016/j.jcv.2009.11.001.
41. Russell PK, Nisalak A, Sukhavachana P, Vivona S. A plaque reduction test for dengue virus neutralizing antibodies. J Immunol 1967; 99:285-90; PMID:6031202.
42. Roehrig JT, Hombach J, Barrett AD. Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral Immunol 2008; 21:123-32; PMID:18476771; http://dx.doi.org/10.1089/vim.2008.0007.